Company: NCEL
Filing Date: 2025-09-04
Form Type: 425
Source: 0001213900-25-084283
Chunk: 5

Company: NewcelX Ltd.
Filing Date: 2025-09-04
Form: 425
Chunk 5
---
 and other documents containing important information about NLS and
Kadimastem and the proposed transaction, once such documents are filed with the SEC through the website maintained by the SEC at http://www.sec.gov.
Copies of the documents filed with the SEC by the Company will be available free of charge on NLS’s website at www.nlspharma.com.

Participants in the Solicitation

NLS, Kadimastem, and certain of their respective directors and executive
officers may be deemed to be participants in the solicitation of proxies from NLS and Kadimastem shareholders in respect of the proposed
transaction. Information about the directors and executive officers of NLS, including a description of their direct or indirect interests,
by security holdings or otherwise, is set forth in NLS’s Annual Report on Form 20-F for the fiscal year ended December 31, 2024,
which was filed with the SEC on May 16, 2025. Other information regarding the participants in the proxy solicitation and a description
of their direct and indirect interests, by security holdings or otherwise, will be contained in the proxy statement/prospectus and other
relevant materials to be filed with the SEC regarding the proposed merger when such materials become available. Investors should read
the proxy statement/prospectus carefully when it becomes available before making any voting or investment decisions. You may obtain free
copies of these documents from NLS Pharmaceutics using the sources indicated above.

Investor & Media Contacts

NLS Contact:

Investor Relations

InvestorRelations@nls-pharma.com

www.nlspharma.com

Kadimastem Contact:

Sarah Bazak

Business Operations
Manager

s.bazak@kadimastem.com

<div align='center'>3</div>